
Prescient Therapeutics welcomes chief medical officer
Prescient Therapeutics (ASX:PTX), a clinical-stage oncology company, announced the appointment of Dr Rosalind Wilson as its new Chief Medical Officer, effective July 13.
Wilson succeeds Dr Marissa Lim, who is stepping down from full-time employment into semi-retirement following significant contributions to the company’s clinical programmes.
An accomplished biotechnology executive with over 30 years of global oncology drug development experience, Wilson brings a wealth of expertise spanning clinical trials, regulatory strategy, and commercial launches.
Her previous leadership roles include serving as Global Head of Drug Development at Telix Pharmaceuticals (ASX:TLX) and CEO of ASX-listed Factor Therapeutics.
Earlier in her career at Roche, she spearheaded the global development and launch strategy for the landmark breast cancer treatment pertuzumab (Perjeta), which significantly accelerated approval timelines.
In her new capacity at Prescient, Wilson will lead the company’s clinical development strategy and execution.
This includes overseeing the advancement of PTX-100 in its ongoing Phase 2 cutaneous T-cell lymphoma study and driving the progression of the broader pipeline.
Prescient CEO James McDonnell expressed strong enthusiasm for the appointment, highlighting that Wilson’s track record in steering therapies from Phase 1 through to commercialisation will be instrumental during this key growth stage.
Frequently asked questions
More from Australia
Immuron hit with 44% first strike vote
Northern Star’s new CEO says performance has fallen short
ASX finds Austral breached rules on A$6.9m deals
Tasmea’s second FY27 guidance upgrade points to 80% earnings growth
MinRes scraps executive exit pay vote as investor support falls short
Woolworths unveils $10b sales growth plan to investors